熱門資訊> 正文
C4 Therapeutics提交价值4亿美元的混合货架产品
2025-11-22 06:15
- C4 Therapeutics (CCCC) has filed a shelf registration to offer up to $400M in securities.
- The offering may include common stock, preferred stock, debt securities, warrants, or units, in one or more combinations and tranches.
More on C4 Therapeutics
- C4 Therapeutics, Inc. (CCCC) Presents at IMS Annual Meeting 2025 Oral Presentation - Slideshow
- C4 Therapeutics, Inc. (CCCC) Special Call - Slideshow
- C4 Therapeutics, Inc. (CCCC) Discusses On Phase 1 Trial Data Of Cemsidomide In Multiple Myeloma Presented At IMS 2025 Transcript
- C4 Therapeutics prices $125M equity offering with warrants
- Seeking Alpha’s Quant Rating on C4 Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
